Cannabinoid-receptor blocker will probably not be sold in the US

The New York Times reports, “The [FDA] advisory panel voted unanimously, 14 to 0, against recommending the drug [rimonabant, Acomplia, Zimulti], saying there was inadequate evidence of its safety. The FDA is not required to follow this advice, but it typically does.”

The report is interesting to this blog because rimonabant works by blocking cannabinoids receptors in the brain. Continue reading Cannabinoid-receptor blocker will probably not be sold in the US →

Shark cartilage: Negative results in lung cancer patients

It has been more than a decade since shark cartilage was first promoted as a potential cure for cancer.

Now, a large study presented during the 43rd American Society of Oncology meeting reports that in patients with non?small-cell lung cancer (NSCLC), shark cartilage added to chemotherapy and radiation treatment had no effect on survival. Continue reading Shark cartilage: Negative results in lung cancer patients →

Complementary and Alternative Medicine: Fair, Balanced, and to the Point